|Montreal, 23 September 2020
The World Anti-Doping Agency (WADA) publishes the revised Technical Letter TL22: Ethylmorphine, which was approved by WADA’s Executive Committee (ExCo) when it met on 14-15 September 2020.
This revised version of TL22 includes a new effective date of 1 January 2021, which should allow enough time for all WADA-accredited laboratories to acquire the relevant reference materials for the validation of their analytical method; and, to implement the Letter. However, WADA will continue to monitor the availability of the required reference materials; and, should they not become available before 1 January 2021, WADA will revise the Letter’s effective date once again.
Under the International Standard for Laboratories (ISL), WADA’s Technical Letters provide specific direction to WADA-accredited laboratories, WADA-approved laboratories for the Athlete Biological Passport, and other stakeholders on particular issues regarding the analysis, interpretation and reporting of results for specific prohibited substance(s) and/or prohibited method(s) or on the application of specific laboratory procedures.
Previously issued Technical Letters are available and indexed on WADA’s website.
Should you have any questions regarding the above Technical Letter, we invite you to contact WADA’s Science Department at: email@example.com.
World Anti-Doping Agency